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ABSTRACT
MODULATION OF AUTOPHAGY IN GBM CELLS BY CLINICAL DOSES OF GAMMA
RADIATION
Devron Ozgen, M.S.
Department of Biological Sciences
Northern Illinois University, 2018
Linda Yasui, Director

Glioblastoma (GBM) is a highly aggressive cancer that forms from the astrocytes of the
brain. Poor prognosis and rather unsuccessful treatment regimens have left researchers and patients
looking for new therapeutic strategies to combat this dreadful disease. Following tumor resection
and radiotherapy combined with temozolomide, survival only remains around 15 months.
Recurrence is very commonly seen and urgently needs to be further understood. Autophagy is an
important mechanism within cancer cells that allows for cellular organelle/amino acid recycling
and thus contributes to energy metabolism. Autophagy machinery has been shown to control cell
death within cancer cells, leading to our interest in radiation’s effect on autophagy and its
completion. To analyze this effect, we set up several methods to help quantify autophagic flux in
GBM cells on Days 0, 3, 5, or 7 after exposure to 0 and 2 Gy gamma radiation. By using autophagic
flux reporters such as p62, we were able to detect flux via protein content over time as well as
visualization and quantification of autophagy changes over time using LC3-eGFP-mCherry
transfected cells. Preliminary results show cells adapt to both nutrient and radiation stress by
maintaining p62 levels, an early stress response gene. Clearly, irradiation induces autophagic flux
in both U87 and U251 cell lines, though in differing fashions. This induction of autophagy differs
however between the cell lines, with U87 seeing changes on Day 3 following irradiation, while

U251 cells see changes on Day 5. These results argue that the increase in sensitivity to radiation
seen in U251 cells could be attributed to a blockage of completion of autophagy seen in the later
days of our experiment, arguing blockage of autophagy could correlate with an decrease in cell
survival following irradiation.
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CHAPTER 1: INTRODUCTION
GBM
Of the nearly 22,000 new cases of neuroepithelial tissue tumors diagnosed annually,
almost half are categorized as glioblastoma (GBM). GBM has an average age-adjusted incidence
rate of 3.2 per 100,000 (Ostrom et al., 2016). GBMs can occur at any age, though they are
frequently diagnosed in patients with an average age of 64 (Thakkar et al., 2014). The risk is
slightly higher for males compared to females and Caucasians compared to non-Caucasians
(Young et al., 2015).
GBM arise from astrocytes within the brain, making it a glioma. Gliomas are categorized
by the World Health Organization into grades I-IV. Grading is based upon histological
characteristics, which correlate with aggressiveness and survival. GBM is a grade IV glioma,
representing the most aggressive form of malignant gliomas (Ostrom et al., 2016).
GBM is also classified as primary or secondary. Primary GBM arises from an unknown
precursor, while secondary GBM is caused by the transformation of a lower grade tumor into a
more aggressive GBM. Primary GBM is the most commonly found tumor in older patients
(mean age = 55 years) and also tends to have a worse prognosis than secondary GBM. The
average age for secondary GBM diagnosis is 40 years old (Wilson et al., 2014). Primary and
secondary GBM also have different gene expression patterns. Primary GBM typically
overexpress epidermal growth factor (EGFR), has phosphatease and tensin homolog (PTEN)
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mutations, and shows a loss of chromosome 10q (Alifieris & Trafalis, 2015). Secondary GBM
commonly has mutations in isocitrate dehydrogenase 1 (IDH1) and p53, while also frequently
losing chromosome 19q (Young et al., 2015).
In this thesis, primary GBM is the focus of study. The first cancer analyzed by the Cancer
Genome Atlas (TCGA) Research Network was GBM. TCGA Research Network identified four
distinct groups of GBM, separated based upon gene expression differences: Classical, Proneural,
Neural, and Mesenchymal (McLendon et al., 2008). Classical GBM tumors are classified by
having increased levels of epidermal growth factor receptor, having no TP53 mutations, and
having the most extended survival between the subgroups in response to aggressive treatment.
Proneural tumors have TP53 mutations about half of the time and are also classified by having
IDH1 gene mutations, which can lead to abnormal growth. Proneural tumors also contain
abnormally high levels of mutated PDGFRA, which can also contribute to uncontrollable
growth. The mesenchymal subgroup is identified as having frequent mutations within the NF1
tumor-suppressor gene, while also having frequent mutations in PTEN and TP53. Neural
subgroup tumors show the same mutations seen in all other subgroups; these mutations did not
occur at an increased or decreased level when compared to different subsets (Verhaak et al.,
2010). These categories provide information on the genetic background of each subset, allowing
for more personalized therapies.
Many studies have been conducted in hopes of determining specific risk factors for
GBM. Numerous factors have been loosely affiliated with GBM formation, such as exposure to
vinyl chloride, pesticides, smoking, petroleum refining, and synthetic rubber manufacturing.
Exposure to ionizing radiation leads to an increase in risk association of GBM formation (Ellor
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et al., 2014). Electromagnetic fields, formaldehyde, and non-ionizing radiation, such as from cell
phones, do not cause GBM formation (Alifieris & Trafalis, 2015). Certain genetic diseases can
also lead to the creation of GBM, though only ~1% of patients with glioma have a known
hereditary disease (Ellor et al., 2014).
Though highly aggressive, GBM initially shows non-specific symptoms, such as
headaches or nausea, which lead to an extremely poor prognosis. Due to the quick proliferation
of cancer, the pressure within the brain is increased, which leads to other symptoms such as
changes in mood or personality, blurred vision, and seizures. The symptoms also are mainly
dependent upon where the tumor is located within the patient’s brain. Initial diagnostics for
GBM can consist of computed tomography scan (CT) or magnetic resonance imaging (MRI)
scan. The presence of necrosis within the tumor is required for cancer to be considered GBM by
the World Health Organization classification (Blissit, 2014).
The primary strategy for combating GBM is a combination of tumor removal surgery,
radiation, and chemotherapy, also known as the Stupp chemo-radiotherapy regimen (Stupp et al.,
2015). Patients are treated with temozolomide, an oral alkylating chemotherapy agent, and
radiotherapy four to five weeks following surgical resection of the tumor (Krex et al., 2007). The
use of tumor-treating fields (TTFields) can increase median survival to 20.5 months in individual
patients. TTFields involve treatment that disrupts the cells’ mitotic cycle by using low-intensity,
intermediate-frequency alternating electric fields via transducer arrays applied to the shaved
scalp (Stupp et al., 2015). Surgical resection of all cancerous cells is very difficult because these
tumors can be very invasive, leading to disease progression or recurrence (Wilson et al., 2014).
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Recurrence is extremely important when devising therapeutic strategies, as tumor
recurrence is almost guaranteed with today’s therapy. Recurrence is brought upon by cells that
survive the initial radiation and chemotherapy, becoming resistant. Recurrence-initiating stemlike cancer cells (RISC), as named by Osuka and Van Meir, should be the focus of future GBM
remedies. Following initial tumor resection, patients generally see no sign of recurrence for a few
months (Stupp et al., 2005). Soon after, tumors tend to recur near the initial resection.
Recurrence is based upon a differing cell population that maintains similar genetics to the
original tumor but has also obtained new mutations (Wang et al., 2016). Tumor reappearance is
greatly variable and can arise from any subpopulation formed from the original tumor. Most
patients show 50-200 clonal or subclonal mutations and can be as high as 1,000 in certain cases
(Osuka & Van Meir, 2017). Recurrence variability, along with the fact that recurrence occurs in
almost every GBM patient, argues that most GBM consist of many subpopulations and should be
targeted as such (Osuka and Van Meir, 2017). These tumor subpoplations are the main cause of
recurrence following resection: removal of the bulk of one population, stabilization, followed by
recurrence of the new subpopulation.

Clinial Trials
Bevacizumab, sold as Avastin, is a clinically used drug for the treatment of many
cancers. Bevacizumab is an anti-VEGF-A (vascular endothelial growth factor A) antibody.
In May of 2009, the US Food and Drug Administration accelerated approval for
bevacizumab. Expedited approval was granted based upon the findings of the European
Organization for Research and Treatment of Cancer, who showed addition of bevacizumab to
lomustine increased progression-free survival (PFS) to 4.2 months instead of 1.5 months for
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lomustine alone (Taphoorn et al., 2015). Combination of the two drugs was also shown to
increase patient survival for recurrent gliolastoma (Taal et al., 2014). The enthusiasm for
bevacizumab treatment was short lived, as bevacizumab neither increased survival time nor PFS
significantly (Gilbert et al., 2014). Bevacizumab is still used in some clinical trials, mainly as a
last effort to combat recurrence (Pasqualetti et al. 2018), though its use has significantly
decreased in clinical trials.
Another drug of specific interest is chloroquine, commonly known to prevent malaria. It
has been shown that chloroquine in combination with temozolamide and radiotherapy improved
median survival time for newly diagnosed GBM from 11.4 to 25 months (Briceño et al., 2007).
The increase in survival was attributed to chloroquine’s ability to block autophagy, thus
increasing the cytotoxicity of temozolomide (Golden et al., 2014). Golden et al. (2014) showed
that authophagy protects cells from temozolomide toxicity, and thus, by blocking autophagy with
chloroquine, cells have an enhanced sensitivity to temozolomide. Chloroquine is still used in
clinical trials (Weyerhäuser et al., 2018). Many new clinical trials are focusing on nutritional
therapies, such as ketogenic and Atkins-based diets (Clinical Trials.centerwatch.com).

Although there are over 200 clinical trials for GBM around the world, the prognosis for
patients with GBM is still bleak. Even with the advancements of surgery and therapy, median
survival remains around 15 months (Thakkar et al., 2014). GBM is a devastating disease because
of its poor prognosis and median survival. Research is needed to help find better ways of
understanding and fighting this horrible disease. Common complications related to GBM are
shown in Table 1.
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Table 1. Common GBM-Related Complications (Davis, 2016).

Cells respond to radiation stress via autophagy, although its direct impact on cell fate is
not clear. More studies are necessary to uncover the role of autophagy in radiation-induced cell
death.
Autophagy
Autophagy is an intracellular catabolic process in which cells can recycle cellular
components during times of nutrient stress, allowing for cell survival. Autophagy can be carried
out in three different ways: macro, micro, or chaperone-mediated autophagy. Micro-autophagy is
the direct addition of cellular cargo to the lysosomal membrane (engulfment). Chaperonemediated autophagy (CMA) has specifically targeted proteins, and chaperone proteins form a
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complex that is recognized by lysosomal membrane receptor proteins, allowing for specifically
targeted degradation. Macro-autophagy utilizes a phagophore, which is a double-membraned
“compartment” that engulfs all cellular protein/organelles targeted for elimination within the
forming multiple-membraned structure called an autophagosome. The phagophore matures into
an autophagosome, which then fuses with a lysosome to become an autolysosome.
Autolysosome formation degrades all content within the membrane. Macro-autophagy is
most associated with its role in the disease (Glick et al., 2010) and is the primary focus of this
thesis. Macro-autophagy consists of three main steps: initiation, nucleation, and elongation.
Autophagy is of significant interest in GBM research because it can directly control cell death
and survival (Goodall et al., 2016). Goodall et al. reported that the autophagy machinery,
specifically p62 and the necrosome, can determine the cell death pathway by acting as a scaffold
for necroptotic signaling and not degrading cargo. p62 recruitment of receptor-interacting
serine/threonine-protein kinase 1 (RIPK1) to the necrosome was sufficient to cause necroptotic
cell death. Cell death switched to apoptosis if p62 recruitment to the autophagy machinery was
blocked (Goodall et al. 2016). p62 and other autophagy machinery allow for the proper
formation of the necrosome and thus necroptosis or programmed cell necrosis. By targeting
formation of the necrosome, GBM therapies may be able to more efficiently kill tumor cells.
Autophagy can be an adaptive survival mechanism that fulfills two major cellular
functions: detoxification through waste removal and conferring resistance to nutrient stress.
Detoxification requires additional adaptor proteins to be able to target specific proteins for
degradation while not targeting healthy organelles (Green & Levine, 2014). Selective autophagy
is essential because it maintains cellular homeostasis through prevention of ER and oxidative
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stress. Selective autophagy can also be viewed as a tumor-suppressor mechanism, as it functions
to prevent the accumulation of oncogenic mutations through the removal of genotoxic
environments (White, 2012). Though this may seem beneficial to the cell, by also conferring
resistance to nutrient stress, autophagy can enhance tumor growth if the cancer cells have limited
access to energy sources. Nutrient stress causes many changes within the cell, including
activation of AMPK and inhibition of mTORC1 (Galluzzi et al., 2014). These changes allow
cells to create energy and nutrients via “bulk” autophagy in times of nutrient stress, often seen in
the context of cancer progression. This “bulk” autophagy mechanism shows no apparent
selectivity, thus allowing the argument that autophagy could also be a tumor promoter as it
allows cells to constantly obtain energy to survive, even while in nutrient-deprived conditions
(Kaur & Debnath, 2015). It is because of these two mechanisms, “bulk” vs. selective autophagy,
that understanding of the entire pathways and how to interpret them are up for debate. Both
mechanisms must achieve a balance to maintain homeostasis so as to not promote tumor
initiation and progression.
Aberrant control of autophagy is a key hallmark of cancer. In some settings, autophagy
can support survival (or not) by either promotion or inhibition of tumorigenesis. Beyond the
selective autophagy studies of Goodall et al. (2016) mentioned above, analysis of gene
transcription in numerous cancers showed that there are pro-autophagic genes, such as LKB1,
PTEN, and p53, and anti-autophagic genes, such as PI3K, Akt, Ras, and Bcl-2, and many of
these genes are over activated (Kimmelman, 2011). In one specific example, autophagy is
capable of reducing rates of tumor growth when pro-autophagic genes are inactivated in mice,
favoring tumor progression (Corcelle et al., 2009).
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In this study, another aspect of autophagy beyond selective autophagy (Goodall et al.,
2016) or pro-autophagic and anti-autophagic genes (Corcelle et al., 2009; Kimmelman, 2010)
was studied. We argue that autophagic flux provides clues for the specific role for autophagy in
radiation-induced cell death. Autophagic flux is challenging to monitor, so two proteins, LC3
and p62, were used here as common biomarkers used to track autophagic flux.
p62
p62, also known as Sequestosome 1 (SQSTM1), is a protein involved in autophagy. p62
is of specific interest because of its use as an autophagy marker. p62 binds ubiquitin
modifications linked to cargo destined for degradation, making p62 an autophagy mediator
(Lippai & Low 2014). p62 levels can be measured to determine how autophagy proceeds in cells
(Bjørkøy et al., 2009). Increase in p62 indicates induction of autophagy while lowering in p62
levels indicates completion of autophagy. However, while p62 can be used as an autophagy
marker, it also has many other functions within the cell, so care must be used in interpretation of
p62 data.

p62 consists of seven domains: N-terminal Phox-BEM1 (PB1) domain, ZZ-type zinc
finger domain, a nuclear localization signal, export motif, LC3-interacting region (LIR), Keap1interacting region (KIR), and C-terminal ubiquitin-associated domain (UBA) (Puissant et al.,
2012). The PB1 and ZZ domains are involved mainly in essential signaling pathways, such as
mTOR, Map Kinase Kinase 3, and NFkB (Duran et al., 2004). More importantly, however, are
the UBA and LIR regions, both dealing with autophagy and ubiquitinated proteins. The UBA
domain binds to ubiquitin bound to lysine residues in proteins destined for degradation
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(Matsumoto et al., 2011). The LIR domain consists of 11 amino acid residues in region 332-343
of p62 that associate with the protein LC3. LC3 proteins are targeted to the autophagosome
membrane as described later and LC3 proteins are essential for the lengthening and closing of
autophagosomes (Puissant et al., 2010). P62 domains and functions can be
p62-Keap1-NRF2
p62 is known to have a plethora of functions within the cell. p62 activates Nuclear Factor
Erytheroid-Derived-2-like (NRF2) via degradation of Kelch-like ECH-associated protein 1
(Keap1) (Dinkova-Kostova et al., 2002). The NRF2-Keap1 pathway protects cells against
oxidative stress (Itoh et al., 1999). Under normal conditions, NRF2 is bound by Keap1,
regulating its signal. Under stressful conditions, Keap1 is degraded via p62 targeting for
autophagy (Komatsu et al., 2010). Phosphorylation on serine-351 by mTORC1-kinase drastically
increases binding affinity to Keap1 (Ichimura et al., 2013). Ichimura et al. (2013) also showed
accumulation of phosphorylated p62 contributed to growth within human hepatocellular
carcinomas (HCCs), arguing that interfering with p62-Keap1 binding could prove therapeutic
when targeting other cancers. Several studies have associated p62 accumulation with tumor
transformation and progression. p62 accumulation is shown to increase NRF2 activation in
autophagy-deficient mice, which was initially thought to be from an increase in oxidative stress.
Oxidative stress response was ruled out, however, when mass spectrometry showed that p62Keap1 direct interaction inhibits the ability of Keap1 to sequester NRF2 and regulate oxidative
stress response (Jiang et al., 2015).
p62 is also necessary for perinuclear sequestering of vesicles from the ER. ER-associated
E3 ubiquitin ligase RING finger protein 26 (RNF26) is responsible for the “architecture of the
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perinuclear cloud.” RNF26 can also recruit p62, allowing for vesicle-bound adaptor molecules
with ubiquitin binding domains to bind p62 and be sequestered in the perinuclear cloud (Jongsma
et al., 2016). Jongsma et al. (2016) also noted three proteins which interact with the RNF26/P62
complex: TOLLIP, EPS15, and TAX1BP1. All have differing effects on the complex, arguing
that this complex is the first mechanism to be identified that can cause such drastic changes
within vesicle transportation and positioning (Dellibovi-Ragheb & Altan-Bonnet, 2016).
LC3

Microtubule-associated protein 1 light chain 3 beta (LC3B) is a soluble protein that is
found in all mammalian tissues. During autophagy, cytosolic LC3-I is conjugated to
phosphatidylethanolamine (PE), thus becoming LC3-II. LC3-II is then recruited to the
autophagosome membranes (Taylor & Kirkegaard, 2007). In response to stresses, such as
nutrient deprivation, autophagosome formation increases, as does LC3-II levels. p62 binds LC3II on the autophagosome membrane. As with p62, LC3-II is degraded at the completion of
autophagy. The amount of LC3-II that can be obtained via immunoblotting is directly related to
the amount of autophagosomes and autophagy-related structures (Yoshii & Mizushima, 2017). It
is important to note that the overall amount of LC3 at a given point of time does not estimate
autophagic activity because LC3-II levels can increase due to induction in autophagy or
inhibition of autophagosome degradation (Gómez-Sánchez et al., 2015).

While immunoblotting is helpful for estimating number of autophagic structures, it is
impossible to estimate autophagic flux without imaging. Cultured GBM cell lines, transduced
with red/green fluorescence pBABE-puro-LC3B-eGFP-mCherry, can be imaged using confocal
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microscopy (Yasui et al., 2016). The fluorescent tags allow for visualization of green, yellow,
and red “puncta.” These puncta show early phase (yellow) and late-phase (red) autophagosomes,
allowing for quantification and a proper way to analyze flux. Autophagy is considered to be
induced when yellow puncta increase, while red puncta also increase. Inhibiting autophagic
induction leads to a decrease in yellow and red puncta. Blockage of lysosome fusion causes an
increase in yellow puncta, while red puncta decrease (Yoshii & Mizushima, 2017).

p62 Regulation
p62 concentration is regulated by a balance between transcriptional regulation and posttranslational degradation (Puissant et al., 2012). p62 is an early stress response gene and can be
transcriptionally regulated by the transcription factor NRF2. When oxidative stressors are not
present, NRF2 is inactive in the cytoplasm bound to the E3 ubiquitin ligase Kelch-like ECHassociated protein 1 (KEAP1) (Itoh et al., 1999). Oxidative stress within the cell leads to NRF2
specifically binding to the antioxidant-response element (ARE) found in p62 promoter, thus
increasing expression of p62 mRNA (Jain et al., 2010). p62 can also bind KEAP1 via its KIR
domain, thus allowing p62 to dissociate NRF2 from KEAP1, which then permits activation of
NRF2 and an increase in p62 transcription (Komatsu et al., 2010). This process allows for p62 to
have a positive feedback loop, where p62 can activate NRF2 to increase its own transcription
(Jain et al., 2010). Transcriptional regulation of p62 can also be independent of NRF2. Many
factors can lead to increased p62 levels within cells, such as phorbol 12-myristate 13-acetate
(PMA), calcium, and IL-3. All act independently of NRF2 and increase p62 mRNA expression
(Lee et al., 1998). Duran et al. (2008) showed that ras-transformed fibroblasts exhibit a high
level of p62 mRNA. These levels are lowered after removal of the AP-1 binding site upstream of
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the p62 promoter, which strongly suggests the constitutive activity of Ras/MEK/ERK1-2
pathways regulates p62 transcription via AP-1 binding domain (Duran et al., 2008).
p62 levels are also effected by post-translational mechanisms (Figure 1). For example,
p62 associates with LC3-II, so p62 is also a target for lyosomal degradation. Conditions that lead
to increased autophagy, such as hypopxia and amino acid deprivation, consequently lead to
degradation of LC3-II and p62 (Klionsky et al., 2008). In contrast, blocking autophagy before
completion leads to an accumulation of p62. p62 domain and functions can be seen in Figure 2
and Table 2, respectively.

Figure 1. Visualization of p62 level effectors de novo (Puissant et al., 2012).
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Figure 2. p62 structure showing associated pathways (Puissant et al., 2012).

Table 2. p62 Domains and Some Functions
p62 Domain

Function

N-terminal Phox-BEM1 (PB1)

-Initially identified by the ability to bind aPKC, which in return
contributes to the activation of IkB kinase, and thus nuclear
translocation of NFkB (Shin 1998)
-MAP kinase kinase 3 (MEKK3) can activate TRAF6 to promote
NFkB nuclear translocation via binding of PB1 (Moscat et al., 2006).
- P62 can also recruit CYLD (de-ubiquitin ligase) via PB1 to inhibit
TRAF6 following NF-kB activation, which is needed for
osteoclastogenesis (Moscat et al., 2006).
-Also necessary for homodimerization, or association with NBR1,
which allows for oligomerization (Lamark et al., 2009).

ZZ-type zinc finger

-Central zinc finger domain interacts with receptor-interacting
proteins (RIP) to modulate NF-kB pathway (Sanz 2000)

Nuclear Localization Signal
TRAF6 binding (TB)

-Regulate the NFkB pathway (Sanz 2000).

Continued on following page
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Table 2. Continued.
-Duran et al. (2008) showed knockdown of P62 by shRNA inhibits
the growth of mTOR hyperactive driven tumor cells
LC3-Interacting Region (LIR)

-Required for elongation and closure of autophagosomes (Mehrpour
et al., 2010).
-Knockdown causes accumulation of ubiquitinated proteins in the
cytoplasm bound to p62 (Kirkin et al., 2009).

Keap1-Interacting Region (KIR)

-Association with Keap1 leads to activation of Nrf2 (Ichimura et al.,
2013)

C-terminal ubiquitin-associated domain (UBA)

-Binds with moderate affinity to ubiquitin bound lysine residues in
position 48, and a strong affinity to lysine 63 (Tan et al., 2008).
-The commonly mutated domain in Paget’s disease (Hiruma et al.,
2008).

Radiation
Radiation is the emission of energy as electromagnetic waves or subatomic particles
through space or medium. In cancer therapy, radiation can be delivered via photons or particles.
Photons, consisting of X-rays and gamma rays, are the conventional modalities for cancer
therapies, while particle therapy, in the form of protons, neutrons, or charged particles, is a more
recent treatment modality.
Radioactive decay has three possible outcomes: release of an alpha or beta particle or
gamma ray. Alpha decay consists of emission of two protons and two neutrons (helium atomic
nucleus). Beta decay involves the release of electrons or positrons as beta rays. Gamma decay
consists of unstable nuclei releasing excess energy via photons or gamma rays. Cesium-137,
which was used throughout the experiments, decays via beta decay. In Cesium-137 decay, 94%
of the time a neutron is converted into a proton and, as a result, a beta particle is released. A
metastable Barium-56 is formed during this decay, and the metastable compound releases its
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excess energy via 0.655 MeV gamma photons, thus producing a stable Ba-56 daughter. It is these
gamma rays which are used for irradiating samples. The other 6% of the time, Cesium-137 beta
decays directly to a stable Ba-56.
Radiation therapy is the standard adjuvant approach for GBM and remains the primary
treatment for unresectable glioblastomas (Barani & Larson, 2015). The Brain Tumor Study
Group (BTSG) started many randomized experiments in the early 1970s to establish radiation
therapy as a standard approach for patient care. These first trials clearly showed a benefit to
receiving post-operation radiation therapy (Walker et al., 1976). Now that radiotherapy was
shown to be beneficial, the next studies determined the most effective doses. Salazar et al. found
in 1979 that treatments over 6,000 cGy led to necrosis of brain tissue, signifying 6,000 cGy may
be the highest dose limit which spares healthy brain tissue while eliminating tumorous cells.
Sixty gray units remains the standard therapeutical dose, delivered in 2 Gy doses five days a
week for six weeks (Stupp et al., 2005). While whole-brain radiotherapy (WBRT) was the
standard before the 1970s, Onoyama et al. (1976) performed studies to analyze the differences
between WBRT and involved-field RT. IFRT irradiates only the area of the tumor, sparing most
of the other healthy tissue. Results showed nearly identical 1-year survival rates with IFRT vs.
WBRT (Onoyama et al., 1976). Ramsey and Brand (1973) compared 4,400 cGy WBRT to 5,300
cGy IFRT, demonstrating improved survival with higher doses delivered to the limited field.
IFRT remains the standard mode of care to this day.
In 2015, Stupp et al. (2015) analyzed differences between TTField irradiation plus
temozolomide and just temozolomide therapy. Irradiation and temozolomide result in an increase
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of median survival from 15.6 months to 20.5 months. This identifies radiation as a significant
focal point of any studies about GBM.
Because of the evidence showing the benefits of RT, we chose to analyze the effects of
therapeutic doses of radiation on autophagy within GBM cells.

CHAPTER 2: MATERIALS AND METHODS
Chemicals
All buffers are listed with the provider for each chemical in the Materials section below.
Cell Culture
The cell lines used in this study were U87 and U251 GBM cells, with U87 first being
acquired from a 44-year-old stage-four patient and the later obtained from a male diagnosed with
malignant astrocytoma. Both cell lines were established at the Wallenberg Laboratory in
Uppsala, Sweden (Westermark et al., 2009). U87 has a wild-type functioning p53, and U251 is
p53 defective (Ponten & Westermark, 1978). Through genomic sequencing, the Cancer Genome
Atlas Research Network has identified subtypes for GBMs, with U87 being mesenchymal and
U251 being in the proneural subgroup (Verhaak et al., 2010).
The cells were maintained in monolayers on T25 flasks in Dulbecco’s modified Eagles
medium (DMEM): F12 (1:1), 10% fetal bovine serum, penicillin (100 units/ml), and
streptomycin (0.5 mg/ml). They were incubated at 37o Celsius and 5% CO2. The cells were
collected using 0.0625% trypsin in Hank’s buffered saline solution (HBSS: 13.41 µM KCl, 0.441
µM KH2PO4, 0.137 M NaCl, 0.15 M NaH2PO4 and 5.51 µM glucose, without Ca2+ or Mg2+) and
0.1 mg/ml versene (EDTA). The collection consisted of discarding the medium and adding 2 ml
of trypsin to wash out medium. The trypsin was then discarded, and a new 1 ml of trypsin and
0.1 ml versene were added, followed by incubation at 37o Celsius for two minutes. Once
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removed, dishes were tapped to detach the cells fully. Once detached, 5 ml medium were added
in the order of ml, 2ml, 2ml, with collection to a centrifuge tube following each addition of
medium. The cells were then centrifuged at 1000 rpm at 4o Celsius for two minutes. The
following was then decanted, re-suspended, and counted via hemocytometer.
Sample Collection
The cells were trypsinized as described earlier and placed into six 60mm plates labeled
with day and treatment: Day 3, 5, or 7; 0 or 2 Gy. The number of cells per dish is shown in Table
3 and was chosen to obtain ~1 million cells when collected.

Table 3. Total number of cells plated for experiments
U87 0Gy

U87 2Gy

U251 0Gy

U251 2Gy

Day 0

1,000,000

1,000,000

1,000,000

1,000,000

Day 3

125,000

150,000

125,000

200,000

Day 5

60,000

80,000

40,000

60,000

Day 7

20,000

25,000

20,000

25,000

For Western blotting, cells were collected by trypsinization, as usual,
washed/resuspended in Dulbecco’s phosphate-buffered saline (PBS), centrifuged and decanted.
The remaining pellet was solubilized using 50% 2x solubilization buffer (2% EDTA, 1%
protease inhibitor cocktail, 10% NaF, 0.5% Na orthovanadate, 36.5% H20). A final concentration
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of 5,000 cells/ µl was obtained. The samples were then sonicated, aliquoted and stored at -4o
Celsius.
Irradiation
The cells were irradiated at room temperature using the Cesium-137 irradiator. The
doserate was 1.67 Gy/minute. Exposure of cells for a total of 72 seconds gave a dose of 2 Gy.
Irradiation is achieved through radioactive decay of Cesium-137, which leads to the production
of a 0.662 MeV gamma photon. Cells were irradiated immediately following plating at room
temperature.
Western Blot
p62 levels were compared using Western blotting. Proteins from solubilized cell samples
were separated using a 12% SDS PAGE (sodium dodecyl sulfate-polyacrylamide gel
electrophoresis). The composition of resolving and stacking gels for a Hoefer Mini VE gel
electrophoresis rig can be found in Table 4 in the Materials section. A 12% resolving gel
consisted of 4 ml H2O, 2.4 ml resolving gel buffer, 70 µl 10% ammonium persulfate (APS), 4.5
µl tetramethylethylene diamine (TEMED), and 3.2 ml 33.33% acrylamide, while stacking gel
was composed of 3.1 ml H2O, 1.25 ml stacking gel buffer (0.5 M Tris-base, 0.4% SDS, pH 6.8),
7 µl TEMED, 40 µl 10% APS, and 0.6 ml 33.33% acrylamide. Once the gel wells were
polymerized, cell samples were removed from the freezer and prepared to be loaded onto the gel
by adding 2x sample buffer (0.125 M Tris-HCl, 6% SDS, 10% 2-mercaptoethanol, 20%
glycerol) in a 1:1 ratio, followed by addition of 2 µl of 1.0M dithiothreitol (DTT). The
solubilized cells were then heated for 3 minutes at 100 o Celsius to denature the protein. An equal
number of cell equivalents were added to each lane (50,000 cells). The gel was run using 1.2
liters of SDS running buffer (0.3% Tris base, 1.4% Glycine and 0.1% SDS). The gel was first run
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at 75 V for ~45 minutes and then, once the dye front reached the resolving gel, power was
increased to 150 V for about ~1.5 hours to obtain complete band separation. PageRuler
Prestained Protein Ladder (Thermo Fisher Scientific, Waltham, MA, USA) was used as a ladder.
Proteins were then transferred to a Bio-Rad 0.45 µm nitrocellulose membrane, utilizing a transfer
buffer containing 39 mM glycine, 48 mM Tris base, 20% methanol, and 0.037% SDS. The
transfer was run for two hours at ~350 mA. The apparatus sandwiched three sponges, two filter
papers, SDS PAGE gel, nitrocellulose membrane, two filter papers, and three sponges from
cathode to anode. Following protein transfer, the nitrocellulose membrane was stained with 10%
Ponceau S for 5-10 minutes to visualize proper protein transfer. When adequate transfer was
detected, the nitrocellulose was washed twice with Tris-buffered saline with Tween20 (TBSTween20, 0.02% Tween 20) for 5-10 minutes, followed by 30 minutes on the shaker in milkTBS-Tween20 (3% dry milk). The nitrocellulose membrane was then placed in a ziplock bag
with 2 ml milk-TBS-Tween20 and primary rabbit antibody (1:1000 ratio), and stained overnight
at 4o Celsius, with shaking. The nitrocellulose membrane was then washed for 5-10 minutes,
twice with milk-TBS-Tween20 and TBS-Tween20. Following these washes, a secondary
antibody stain, in a 1:7500 ratio (1 ul antibody in 7.5 ml milk) was added to the nitrocellulose
membrane and the solution was shaken for 1 hour. The nitrocellulose was then washed three
times with milk-TBS-Tween20, TBS-Tween20, and TBS. The p62 bands were then stained with
an alkaline phosphatase color development kit for about 30 minutes. Following AP color
development, the nitrocellulose membranes were imaged using the Kodak gel logic 200 imaging
system, utilizing Kodak 1D Image Analysis software version 3.6 (Kodak, Rochester, NY, USA).
The software was used to analyze the intensity of the bands, of which the intensities were then
normalized to Day 0.

22

Measurement of Autophagic Flux
U87 and U251 cells expressing LC3-eGFP-mCherry were transferred to 35 mm Petri
dishes containing a sterile 22 mm2 square coverslip in the medium (Corning, Corning, NY,
USA). The cells were irradiated with 0 or 2 Gy following plating. On Days 3, 5, and 7 following
plating, the cells were imaged and analyzed using a Zeiss LSM 5 Pascal confocal laser scanning
system (Zeiss, Thornwood, NY, USA). Images were acquired at 1024x1024 pixel sampling size
and 8-bit data depth. Images were obtained using differential interference contrast (DIC), 40x
objective lens, with a 0.5 um interval between z-stacks. The images were analyzed using LSM
Image Browser version 4.2.0.121. Thirty cells per group were circled, extracted, and analyzed
for puncta counts (Zeiss, Thornwood, NY, USA).

Bradford Assay
Bradford assay was performed to determine the total protein content in U87 or U251 cells
across seven days. The tests were performed using 50,000 cells. Cells were collected as
described earlier, and the cell pellets were dissolved in 0.3 N NaOH and 1% SDS for 30
minutes. After the cells were solubilized, 1 ml of Bradford Reagent containing Coomassie blue
was added to cells. The samples were mixed and left to stand for ~10 minutes at room
temperature. After ten minutes, the samples were read using a spectrophotometer at 595 nm. A
standard curve was created using known concentrations of BSA.
Flow Cytometry
Cells were grown and irradiated as previously stated. Cells were collected as usual and
immediately fixed in a 2% paraformaldehyde PBS solution for 10 minutes at 37oC in the tissue
culture incubator followed by 10 minutes on ice. The cells were then spun down, as usual,
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decanted, washed with PBS, and stored in 90% methanol in PBS solution at -20°C, until all
samples were collected. Once all days were sampled, the samples were spun down, decanted,
washed with PBS, and resuspended in 1 mL PBS. Ten 12x75mm tubes were then labeled 1-10,
indicating the following cell day and stain:

1- Day 0 – Unstained control
2- Day 0 – P62 conjugated Alexa 488 single color control
3- Day 0 – 7AAD single color control
4- Day 0 – 2 color
5- Day 3 0Gy – 2 color
6- Day 5 0Gy – 2 color
7- Day 7 0Gy – 2 color
8- Day 3 2Gy – 2 color
9- Day 5 2Gy – 2 color
10- Day 7 2Gy – 2 color

One hundred microliters of Day 0 PBS solution was transferred to Tubes 1 and 3. Nine
hundred microliters of PBS were added to 10x75mm tubes to make a total of 1mL/tube. Samples
were then stored at 4°C while the remaining samples were then blocked with 1mL of 0.5% BSA
in PBS solution for 30 minutes on ice. Following blocking, the samples were centrifuged and
decanted. A p62 conjugated Alexa 488 antibody dilution of 1:400 in PBS was then made, and
200 µL of antibody were added to all samples and shaken on ice for one hour. Following one
hour, 1mL of PBS was added to dilute the antibody, centrifuged, decanted, and washed with
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PBS. Samples were then resuspended in 1mL PBS, and 200 µL of Day 0 p62-stained sample
were added to Tube 2. PBS was then added back to the sample, and all samples were transferred
in 1mL of PBS to their respective 10x75mm tube. A dilution of 7-AAD in PBS (1:100) was then
made and added to Tubes 3-10. The samples were covered with aluminum foil to limit light
exposure and incubated for 30 minutes. That concludes cellular setup for flow cytometry.
When cells were run through the flow cytometer, 10,000 events were collected. The graphs
used to analyze were as follows: forward scatter x side scatter, with a gate centered on ~400 and
102, FL3-H x FL1-H, FL3-W x FL3-H, and FL1 x frequency count.

RNA Isolation and Quantification
RNA isolation was performed on ~1x106 cells. Cells were grown to confluency and
suspended in 1 ml Trizol and transferred to a 1.7 ml Eppendorf tube. Samples were stored at
70 °C until isolation. Once thawed, samples were kept on the ice, and 200 µl of chloroform were
added to each sample. The tubes were then vortexed and stored on ice for five minutes. Cells
were then centrifuged for fifteen minutes at 17,000 x g at 4°C. The supernatant was transferred to
a new 1.7ml Eppendorf tube, and 500 µl of isopropanol were added to each sample. Tubes were
inverted several times and placed on ice for five minutes and centrifuged at 17,000 x g for 15
minutes. Isopropanol was decanted, and 1 ml of 75% ethanol was added to each sample, set on
ice for five minutes, and centrifuged at 17,000 x g for 5 minutes. The ethanol was decanted, and
the remaining pellets were left to dry for 1-2 hours under the fume hood. Pellets were then
suspended in 20-30 µl of nuclease-free H2O (NF H2O), depending on the size of the pellet.
Samples were then frozen to -20oC until quantification.
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Thawed samples were then incubated at 65oC for fifteen minutes to resuspend the RNA
pellet. RNA was quantitated using a Nanodrop spectrophotometer. The Nanodrop 2000
software was then opened and set to analyze ssRNA. The apparatus was first blanked with one µl
of nuclease-free (NF) H2O, followed by measurement of one µl of each sample.
cDNA synthesis from the isolated RNA was accomplished as described here. Dilutions of
12 microliters were prepared containing 2500 ng of RNA in 0.2 ml Eppendorf tubes. One µl of
decamers was added to each sample and placed in a thermocycler for five minutes at 70oC to
anneal primers. Seven µl Master Mix for cDNA synthesis (4 µl MLV RT 5x Buffer, 1 µl NF
H2O, 1 µl MLV Reverse Transcriptase, 1 µl 10mM dNTPs) were then added to each sample.
Tubes were then put back in a thermocycler for one hour at 37oC, five minutes at 95oC to
denature RT, then held at 4oC. Samples were then diluted with 40 µl of NF H2O.
cDNA samples, p62 primers, GAPDH primers, and qPCR plate were kept on ice while
preparing Master Mix for qPCR. Samples were run in triplicate, and p62 relative expression was
determined by comparing p62 Ct values to GAPDH Ct values for each corresponding sample.
Each reaction well was filled with 3 µl of cDNA sample and 17 µl of Master Mix (10µL 2x
Applied Biosystems Fast SYBR with ROX reference dye, 1µL of 10µM forward primer stock,
1µL of 10µM reverse primer stock, and 5µL NF H2O). qPCR was run at 95°C for twenty
seconds for initial denaturation, then cycled 40 times at 95°C for three seconds to denature,
followed by 60°C for thirty seconds to anneal/extend. After the 40 cycles were completed, the
plate was held at 4°C.
The p62 primer sequence was based on the p62 primer used by Sahani et al. (2014) and is
indicated below:

Forward Primer - GATTCTGGCATCTGTAGGGACTGGAGTTCACC
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Reverse Primer – GATGGAGTCGGATAACTGTTCAGGAGGAGATG

GAPDH primer sequence was from Vandesompele et al. (2002) and is indicated below:
Forward Primer - GACCACTTTGTCAAGCTCATTTC
Reverse Primer – CTCTCTTCCTCTTGTGCTCTTG
Materials
Table 4. List chemicals and buffers
Chemical name
TISSUE CULTURE

Source

CAS/catalog

Dulbecco's modified eagle medium (DMEM) high glucose

Gibco

12100-046

Ham's F-12 medium

Gibco

21700-075

10% fetal bovine serum

Gibco

26140-079

100 units/ml penicillin

Fisher

BP914-100

0.5 mg/ml streptomycin

Sigma

3810-74-0

Gibco

15090-046

130.6 mM KCl

Sigma

7447-40-7

4.4 mM KH2PO4

Sigma

P-5379

1.37 M NaCl

Fisher

7647-14-5

3.7 mM NaH2PO4

Sigma

7558-79-4

55.5 mM glucose

Sigma

50-99-7

U87/U251 cell medium (DMEM:F-12)

0.0625% Trypsin in Hank's balanced saline solution (HBSS)
10 X HBSS without Ca++ or Mg++
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Versene
Na4EDTA

Puromycin

Sigma

ED4SS

MP Biomedicals

100552

WESTERN BLOTS

Sigma

106K8305

20 mM HEPES

Sigma

7365-45-9

500 mM NaCl

Sigma

7647-14-5

1% Triton X-100

Sigma

t-6978

1 mM Na orthovanadate

Sigma

13721-39-6

2 mM EDTA

Sigma

6381-92-6

1% Protease Inhibitor Cocktail

Sigma

P8340

10 mM NaF

Acros Organics

7681-49-4

Dulbecco's phosphate buffered saline (PBS)

2X solubilization buffer (final concentration)

0.2 M Dithiolthreitol (DTT) (final concentration)

Fisher

12/3/3483

SDS PAGE gel
APS

Sigma

7727-54-0

TEMED

Sigma

110-18-9

29.2% (w/v) acrylamide

Bio-rad

161-0101

0.8% bis-acrylamide

Bio-rad

161-0201

30% Acrylamide
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Lower Resolving Gel Buffer, pH 8.8
1.5 M Tris
36.9 gm/L Tris-HCl

Fisher

77-86-1

153.9 gm/L Tris-Base

Fisher

M-15862

Bio-rad

161-0302

0.5 M Tris-HCl

Fisher

77-86-1

0.4% Sodium Dodecyl Sulfate(SDS)

Bio-rad

161-0302

0.025 M Tris-base

Fisher

M-15862

0.192 M glycine

MP Biomedical

0.1% SDS

Bio-rad

161-0302

Sigma

56-81-5

Mallinckrodt

60-24-2

6% Sodium Dodecyl Sulfate(SDS)

Bio-rad

161-0302

0.125 M Tris-HCl, pH 6.8

Sigma

1185-53-1

Dash Bromphenol Blue

Sigma

62625-28-9

62.5 ml Coomassie blue stock solution

Bio-rad

161-0406

250 ml methanol

Fisher

67-56-1

50 mls acetic acid

Acros Organics

631-61-8

0.4% Sodium Dodecyl Sulfate(SDS)

Upper Stacking Gel Buffer, pH 6.8

Running buffer

808822

2x Sample Buffer
20% Glycerol
-mercaptoethanol

1% Coomassie blue R-250 stock solution in ddH2O

Working Coomassie blue stain
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add ddH2O to 500 mls

Coomassie blue destaining solution
50% methanol

Fisher

67-56-1

10% acetic acid

Acros Organics

631-61-8

Gard's transfer buffer
39 mM Glycine

MP Biomedical

48 mM Tris-Base

Fisher

77-86-1

0.037% Sodium Dodecyl Sulfate(SDS)

Bio-rad

161-0302

20% Methanol

Fisher

67-56-1

FIsher

6226-79-5

2 gm Ponceau S

Sigma

P3504

30 gm Trichloroacetic acid

Sigma

T-4885

30 gm sulfosalicylic aid

Sigma

S3147-100G

Sigma

P3504

50 mM Tris-HCl, pH 7.5

Fisher

77-86-1

150 mM NaCl

Fisher

7647-14-5

Bio-rad

170-6531

Ponceau S stock solution

808822

Add H2O up to 100 mls

Working solution of Ponceau S
1 part Ponceau S stock solution + 9 parts ddH2O

Tris-buffered saline (TBS) (1X)

TBS-Tween 20
0.02% Tween 20 in TBS
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Dry milk-TBS-Tween 20
3% Dry milk in TBS Tween 20

p62/SQSTM1 mAb, rabbit
1o antibody in milk-TBS-Tween 20

CellsSignal.com

(D5E2) 8025S

100 mM Tris-HCl

Fisher

77-86-1

100 mM NaCl

Fisher

7647-14-5

5 mM MgCl2

Sigma

7791-18-6

AP conjugated IgG, anti-rabbit

Promega

S3731(S373B)

BCIP/NBT Color Development Substrate Kit

Promega

S3771

Sigma

106K8305

Sigma

1310-73-2

100 mg Coomassie Brilliant Blue G-250

Bio-rad

161-0406

50 mls 95% ethanol

Pharmco-Aaper

111ACS200

Alkaline phosphatase buffer, pH 9.0

BCIP
NBT

Bradford protein assay

Wash cells with PBS
Dulbecco's PBS

Solubilize cell pellet
100 µl 0.3 N NaOH

Bradford reagent
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100 mls 85% phosphoric acid

Mallinckrodt

2796-8

Fisher

9048-46-8

KCl

Sigma

7447-40-7

Sodium Phosphate Dibasic Anhydrous

Sigma

S-0751

Potassium Phosphate monobasic anhydrous

Sigma

7778-77-0

Anti-p62 Alexa Fluor488

EMD Millipore Corp.

MABC32-AF488

7-Aminoactinomyocin D (7-AAD)

Thermo Fisher

A1310

Blocking Reagent (0.5M BSA in PBS)

Fisher

9048-46-8

Fisher

67-56-1

Trizol Reagent

Ambion

15596018

Nuclease-Free Water (not DEPC-Treated)

Invitrogen

AM9930

Chloroform

Fisher Scientific

25377-72-4

Isopropanol (+99.5%)

Acros Organics

149320050

95% Ethanol

Pharmco-Aaper

111ACS200

M-MLV Reverse Transcriptase Kit

Promega

M1701

Random Decamers - NNNNNNNNNN

Sigma

18204-deca

10mM dNTP Mix - PCR Grade

Invitrogen

Add ddH2O up to 1 L
0.5 mg/ml BSA

Flow Cytometry
Staining

Storage
90% Methanol in PBS
RT-qPCR
RNA Isolation

cDNA Synthesis

100004893

qPCR
Fast SYBR Green Master Mix

Applied Biosystems

0.2mL Skirted 96-Well PCR Plate

Thermo Scientific

Optical Adhesive Covers

Applied Biosystems

GAPDH Forward Primer - GACCACTTTGTCAAGCTCATTTC

Sigma

4385612
AB-0800/G
4360954
18235-GAPDH-F
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GAPDH Reverse Primer - CTCTCTTCCTCTTGTGCTCTTG

Sigma

18236-GAPDH-R

p62 Forward Primer - GATTCTGGCATCTGTAGGGACTGGAGTTCACC

Sigma

16109-p62

p62 Reverse Primer - GATGGAGTCGGATAACTGTTCAGGAGGAGATG

Sigma

16108-p62

CHAPTER 3: RESULTS
Total Cellular Protein Content (Bradford Protein) Analysis
GBM cells change size and shape several days after ionizing radiation. To determine if
total protein levels also change, a Braford protein assay was run. The effects of nutrient stress on
total protein concentration was also measured in sham irradiated samples.
Bradford analysis was performed to quantify total protein concentration change over the
course of seven days, with cells being collected as previously described. Total protein
concentration increased from Day 0 samples to Day 3 samples in both control and irradiated
groups. U87 cells collected on Day 5 had total protein concentration also higher than samples
collected on Day 0 in both sham and irradiated assays. Total protein concentration for U87 cells
collected on Day 5 drops when compared to Day 3 cell’s total protein levels, falling somewhat
more in irradiated samples. Total protein concentration for cells collected on Day 7 were greater
than Day 0 in both samples. Following ANOVA and Tukey’s multiple comparisons test, no
significant differences were found to exist between any of the days or between control and
irradiated. Figure 3 shows no significant change in total protein concentration was seen over time
under nutrient stress. No significant change in total protein concentration was seen in U87 cells
exposed to 2 Gy irradiation or also under nutrient stress. There was also no significant difference
between 2 Gy and sham irradiated samples both under nutrient stress.
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Figure 3. Total protein concentrations for wt U87 GBM, relative to Day 0. Results show the
mean value for cellular protein content from 50,000 cells +/- SEM of two separate biological
repeats, with three technical repeats. ANOVA and Tukey’s multiple comparisons test were
applied, and no statistically significant differences were found.
Total cellular protein concentration was also measured in U251 cells (Figure 4). Much
like U87 cells, no significant difference was seen in total protein concentration after time
following nutrient stress. Following ANOVA and Tukey’s multiple comparisons test, no
significant differences were found to exist between any of the days or between control vs.
irradiated. There was also no significant differences seen in time after exposure to 2 Gy
irradiation and nutrient stress. No significant differences existed between both 2 Gy and sham
irradiated samples. The change in total protein concentration does correlate with the changes of
levels of p62 shown later.
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Figure 4. Net relative total protein concentrations for wt U251 GBM, relative to Day 0. Results
show mean value for cellular protein content from 50,000 cells +/- SEM of two separate
biological repeats, with three technical repeats. ANOVA and Tukey’s multiple comparisons test
were used to analyze statistical significance. Averages are based on 50,000 cell count.

Immunoblotting of p62 Levels
One protein, p62, is used as a reporter for autophagic flux. The levels of p62 was

0 Gy

2 Gy

determined, via immunoblot, in U87 cells exposed to 0 or 2 Gy gamma rays under increasingly
nutrient-stressful conditions. Levels will increase upon an influx of autophagy induction and will
decrease as autophagy completes, though many other factors can effect p62 levels as can be seen
in Figure 2. SDS PAGE separation of proteins and successful transfer were confirmed via
Ponceau red staining, as seen in Figure 5.
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Figure 5. Nitrocellulose membrane following protein transfer and Ponceau S staining from U87
cell samples and a representative blot following AP staining.
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Nitrocellulose membrane was then washed to remove the Ponceau red stain and then the
membrane was washed and stained for p62 as usual; a photo was taken following analysis
(Figure 5). The Ponceau S stained membrane in Figure 5 shows transfer efficiency. Day 3 p62
levels increased from Day 0 to Day 3 in both control and irradiated samples, with Day 3 seeing a
more substantial increase. Day 5 also had increased p62 levels compared to Day 0, though levels
in control samples decreased compared to Day 3 while remaining reasonably stable in irradiated
samples. Day 7 levels were similar to Day 0 levels in control samples, while Day 7 had increased
p62 levels when irradiated. Following analysis with ANOVA and Tukey’s multiple comparisons
test, it was determined that 2 Gy irradiation has no significant effect on p62 levels (Figure 6).
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Figure 6. Relative p62 levels following 0 or 2 Gy irradiation in wt U87. Graphs represent mean
value for cellular p62 content relative to Day 0 from 50,000 cells +/- SEM of two biological
repeats, each with two technical repeats of U87 wt GBM cells.

Western blots were also performed in U251 cells to quantify p62 levels based upon day
and irradiation, as described previously. The averaged value for the U251 cell sample collected
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three days after sham treatment was the only sample that was found to be significantly greater
(p=0.0026) than Day 0.
Samples collected on Days 5 were greater than Day 0, while cells from collected on Day
7 were lower than Day 0. Neither samples collected on Day 5 nor 7 were significantly different
from cells collected on Day 0.
Samples exposed to 2 Gy irradiation and nutrient stress saw an increase in p62 levels on
all days, with the peak being Day 5. There was no significant differences found between any of
the days for irradiated samples.
Both 0 and 2 Gy samples were compared, and no significant differences in p62 levels
were noted between samples and days collected. Sham irradiated samples show a peak of p62 on
Day 3, whereas irradiated samples peak on Day 5. Overall p62 levels are greater in the irradiated
samples, though not significantly.
Following analysis with ANOVA and Tukey’s multiple comparisons test, it was
determined that 2 Gy irradiation has no significant effect on p62 levels (Figure 7 and 8).
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Figure 7. Relative p62 levels following 0 or 2 Gy irradiation in wt U251. Graphs represent mean
value for cellular p62 content relative to Day 0 from 50,000 cells +/- SEM of two biological
repeats, each with two technical repeats of U251 wt GBM cells.
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Figure 8. Representative U251 p62 Western blot.
Comparison between U87 and U251 samples shows some similar trends (Figure 9), such
as both sham irradiation p62 level peaks being collected on Day 3. Both irradiated also have
greater p62 levels when compared to their sham irradiated couterparts, though neither are
statistically significantly different.
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Figure 9. p62 RNA relative levels in U251 and U87 cells.
p62 levels were to examine expression levels following 0 and 2 Gy gamma irradiation.
Exposure to irradiation induced increasing expression in both cell lines. U87 sham irradiated
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samples saw a decrease on Day 3 but steadily increased after, with higher expression being seen
on Days 5 and 7 for sham irradiated samples. U251 show similar trend, largely increasing on
Day 3, remaining similar on Day 5, and dropping on Day 7.
Flux
Another way to describe flux is through comparison of puncta data. Samples were
exposed to 0 or 2 Gy irradiation and imaged. Puncta totals were then averaged and compared
(Figures 10-13). All puncta numbers were compared to samples imaged on Day 0. Increase in
both yellow and red puncta indicate induction of autophagy, while a decrease in both puncta is a
result of autophagy inhibition upstream of autophagosome formation. An increase in yellow
puncta and a decrease in red puncta indicate inhibition of a downstream step in autophagy
(Yoshii & Mizushima, 2017).
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Figure 10. Puncta counts in U87 comparing only nutrient stress to 2 Gy irradiation and nutrient
stress.
Yellow puncta increased on Day 3 following 0 Gy irradiation, while yellow puncta
decreased on Days 5 and 7. Red puncta increased on all days, with the most significant increase
being on Day 3. Day 5 and Day 7 red puncta following 0 Gy irradiation were very similar.
Yellow puncta increased compared to Day 0 for all irradiated samples, with the greatest increase
being Day 5. Red puncta also followed a similar trend, rising in all samples, with all being very
similar. Two gray-unit irradiated samples show a higher number of puncta in both colors. When
compared to Day 0, Day 3 sham irradiated samples showed there was an induction of autophagy,
followed by a decrease in yellow puncta and increase in red, showing completion of autophagy
on Days 5 and 7. Irradiated samples showed autophagy induction, compared to Day 0, on Days
3, 5, and 7.
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Nutrient stress samples (0 Gy) showed an increase in induction of autophagy on samples
collected on Day 3, with yellow puncta (p=0.0205) and red puncta (p=0.0004) being greater than
samples imaged on Day 0. No other significance was noted until yellow punta decreased on Day
7 compared to Day 0 images (p=0.0055), showing an increase in red punca indicating a slowing
of autophagic flux by Day 7.
Nutrient stress and 2 Gy irradiated samples show an induction of autophagy on all
imaged days compared to Day 0 images.
When comparing nutrient stress only to irradiated samples with nutrient stress, clearly the
irradiated samples undergo autophagic flux at a greater pace. Yellow puncta in irradiated
samples were significantly greater than sham irradiated cells, as seen in Figure 11. Red puncta
were also significantly higher in irradiated samples, arguing that autophagy is occurring much
more rapidly than when under only nutrient stress.
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Figure 11. Comparison of U87 puncta counts compared to day zero.
When comparing nutrient stress only to irradiated samples with nutrient stress, clearly the
irradiated samples undergo autophagic flux at a greater pace. Yellow puncta in irradiated
samples were greater than sham irradiated cells, as seen in Figure 12. Red puncta were also
higher in irradiated samples, arguing that autophagy is occurring much more rapidly than when
under only nutrient stress.
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Figure 12. Comparison of U251 puncta counts compared to day zero.
Puncta increases and decreases are the same as described for U87s. Yellow puncta
increased compared to Day 0 in all 0 Gy samples. Red puncta also increased in all samples, with
the greatest increase being Day 7. Two gray-unit irradiated samples also showed an increase in
yellow puncta on all days, with a peak on Day 5. Red puncta also increased on all days, with Day
7 being the peak.
Comparing only nutrient stress samples (0 Gy), autophagy is continually induced, as seen
in Figure 13. Red puncta are significantly greater than Day 0 images for images collected on
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Days 5 and 7 (p=0.0110, p<0.0001) respectively. No yellow punctas are significantly different
compared to Day 0 following increasing nutrient stress.
Irradiated and nutrient-stressed samples follow a similar trend, though these puncta
counts are greater than their only nutrient-stressed counterparts. Images on Day 5 compared to
Day 0 images show a significant increase in both yellow and red puncta (p<0.0001), as well as a
significant increase in red puncta on Day 7 (p<0.0001).

45

D 0 -D 7 0 G y R e d P u n c ta

D 0 - D 7 0 G y Y e llo w P u n c t a
10

A v e r a g e # R e d P u n c ta

10

8

6

4

2

< 0 .0 0 0 1
8

0 .0 1 1 0
6

4

2

7
R

e

d

D

5
R

e

d

D

3
e
R

Y

e

ll

R

o

e

d

d

D

D

7
w

D
Y

Y

e

e

ll

ll

o

o

w

w

D

5

3
D

0
D
w
o
ll
e
Y

0

0

0

D 0 -D 7 2 G y R e d P u n c ta

D 0 - D 7 2 G y Y e llo w P u n c t a
< 0 .0 0 0 1

< 0 .0 0 0 1

10

10

7

5

D

D

R

e

d

d

D
d
e
R

w
ll
e
Y

Y

e

ll

o

w
o

o
ll
e
Y

D

5
D

D
w

D
w
o
ll
e
Y

e

0

R

0

3

2

D

2

d

4

e

4

R

6

7

6

3

8

0

8

0

< 0 .0 0 0 1

Figure 13. U251 puncta comparison.
When comparing nutrient stress only to irradiated samples with nutrient stress, irradiated
samples are greater than non-irradiated samples. Irradiated samples undergo autophagic flux at a
greater pace, as can be seen in Figure 12. This increase in autophagic flux could be attributed to
lack of a functional p53 within the U251 cell line.

CHAPTER 4: Discussion
To summarize data collection for this thesis, data was first compared between U87 and
U251 cell lines to analyze effects of nutrient stress at 0 and 2 Gy irradiation (Table 5).
Table 5. U87vsU251 Protein Content

Day 0
Day 3
Day 5
Day 7

U87 0Gy
16.65
25.01
21.68
20.15

U87 2Gy
16.65
26.57
19.02
20.43

U251 0Gy
25.93
25.05
30.27
25.65

U251 2Gy
25.93
28.34
25.88
27.11

Total protein concentrations were found to help understand the effects of radiation and
nutrient stress on GBM cells. Protein content is different when comparing cell lines. U251 cells
are larger and average greater cellular content than U87 cells, 26.6 ug to 20.7 ug, respectively.
Both cell lines, however, maintain total cellular protein content regardless of increasing time of
nutrient stress. Both U87 and U251 cells also were not affected by exposure to 2 Gy gamma
radiation. Although total cellular protein content in U87 cells was more variable than the total
cellular protein content in U251 cells, total cellular protein levels remained fairly constant in
both cell lines over time following nutrient and radiation stress, so total cellular protein changes
do not likely play a role in autophagic flux.
Exposure to 2 Gy gamma rays induced a consistent, though not statistically significant,
decline in p62 in U87 cells (Table 6). Exposure to 2 Gy induced an initital decline in p62 levels
in U251 cells at Day 3, but by Days 5 and 7, p62 levels had increased. Irradiation appears to
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decrease p62 levels from Day 0 to 3 in both cell lines, perhaps blocking autophagy initially. p62
levels then decrease from Day 3 to 5 in 0 Gy samples, while remaining similar in U87 and
increasing in U251. All samples see a decrease in p62 levels form Day 5 to 7. Immunoblot data
indicates that autophagic flux is blocked at later stages in U251, seen as an accumulation of p62.
Although U251 cells showed greater total cellular protein concentration, they show lower
cellular p62 levels than U87 cells.
Table 6. U87vsU251 p62 Content

Day 0
Day 3
Day 5
Day 7

U87 0Gy
1
1.34
1.13
1.01

U87 2Gy
1
1.23
1.22
1.10

U251 0Gy
1
1.26
1.09
0.885

U251 2Gy
1
1.06
1.22
1.10

Average fold difference was found in both U87 and U251 cells to further understand how
nutrient and radiation stress effect p62 expression levels (Table 7). Exposure to 2 Gy induced
increasing expression in both cell lines. U251 samples showed a slight decrease on day 7
following irradiation. U87 samples saw a decrease on Day 3 but continued a steady increase
after. A higher expression was seen in Days 5 and 7 of sham irradiated U87 samples. U251 cells
showed a greater expression on Days 5 and 7. The increasing p62 mRNA with nutrient and
radiation stress does not correspond to the p62 protein levels seen via immunoblot, arguing that
rapid turnover of p62 mRNA to maintains levels or rapid degradation of p62.
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Table 7. qPCR U87vsU251 Average Fold Difference

Day 0
Day 3
Day 5
Day 7

U87 0Gy
1.00
0.859
2.55
3.34

U87 2Gy
1.00
1.19
2.09
3.26

U251 0Gy
1.00
3.17
3.27
2.99

U251 2Gy
1.00
2.85
3.71
3.57

Radiation Effect
The puncta data was first compared within cell lines to compare the effects of nutrient
stress and 2 Gy irradiation. Three days after plating and irradiation, yellow and red puncta
significantly increased in both 2 Gy and sham irradiated samples. Five days following plating,
un-irradiated samples return to puncta levels comparable to Day 0 controls, while yellow and red
puncta remained elevated in 2 Gy samples. On Day 7, a significant increase in number of red
puncta remains in samples exposed to 2 Gy, while un-irradiated continue to decrease. Clearly, 2
Gy irradiation induces autophagy in U87 cells.
Table 8. U87vsU251 Puncta Count Averages

Day 0 (Yellow)
Red
Day 3 (Yellow)
Red
Day 5 (Yellow)
Red
Day 7 (Yellow)
Red

U87 0Gy
6.0
4.4
7.7
6.7
5.6
5.2
4.3
5.1

U87 2Gy
6.0
4.4
7.9
6.8
8.3
6.9
7.2
6.5

U251 0Gy
4.9
3.5
5.9
4.2
6
5.4
5.8
6.6

U251 2Gy
4.9
3.5
5.9
5.1
8.6
6.8
5.9
8.2
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U251 cells have very comparable puncta counts three days following sham and 2 Gy
irradiation. Five days following plating and irradiation, an increase in yellow and red puncta is
seen in 2 Gy irradiated samples while sham irradiated samples remain fairly constant. Seven
days following plating showed a significant increase in number of red puncta in both sham and 2
Gy samples. Clearly, 2 Gy irradiation induces autophagy in U251 cells, though we are seeing its
effects on Day 5 following plating, compared to Day 3 with U87 cells. We also see a significant
accumulation of red puncta in both sham and 2 Gy samples of U251 cells, not seen in U87 cells.
Blockage of the completion of autophagy could be attributed to expression of a null p53 in U251
cells, while U87 have wt p53.
In conclusion, radiation clearly increases autophagic flux within GBM cells. This
increase appears to be correlated with the dose of irradiation. U251 cells appear to have
autophagy inhibited at a later stage, seen as red puncta accumulation, which could be attributed
to a null p53 expression. This blockage is not seen in U87 with functional p53, arguing lack of
p53 could contribute to an inhibition of autophagy. Blockage of autophagy completion also
correlates with increased sensitivity to radiation seen in U251 cells. Because this blockage is not
seen in U87 cells, we argue that by blocking late-phase autophagy, cells become more sensitive
to radiation, correlating with the surivival standards we know. The puncta data also clearly
shows that autophagic flux proceeds differently in U87 cells compared to U251 cells. U87 shows
effects three days following plating and irradiation, while U251 shows effects following five
days. Though autophagic flux is different, all data indicates that both cell lines adapt to stress by
maintain p62 levels, signifying an important future area of study.
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